26.59% to Target, Deutsche Bank Reconfirms ‘”Buy”’ Rating on AstraZeneca PLC (LON:AZN) Shares Today


AstraZeneca PLC (LON:AZN) Rating Reaffirmed

Deutsche Bank now has a GBX 5700.00 TP on the 56.76 billion GBP market cap company or 26.59% upside potential. In analysts note shared with investors and clients on 18 December, AstraZeneca PLC (LON:AZN) shares have had their “Buy” Rating maintained by expert analysts at Deutsche Bank.

From a total of 28 analysts covering AstraZeneca PLC (LON:AZN) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 94.49 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 70.52 with a 7.14% above today’s (GBX 4502.56) stock price. AstraZeneca PLC was the topic of 124 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on December 17 with “Buy” rating. Handelsbanken maintained shares with “Accumulate” rating and GBX 4959.33 target share price in a report from a December 4. Bernstein maintained AZN stock in a recent report from December 10 with “Market Perform” rating. UBS maintained the rating on November 25. UBS has a “Buy” rating and a GBX 5000 price target on shares. Finally, Jefferies maintained the stock with “Buy” rating in a report issued on a December 7.

The stock increased 1.95% or GBX 86.06 on December 17, striking GBX 4502.56. Approximately 2.37 million shares of stock traded hands or 12.32% up from the average. AstraZeneca plc (LON:AZN) has risen 0.20% since May 21, 2015 and is uptrending. It has outperformed by 2.47% the S&P500.

26.59% to Target, Deutsche Bank Reconfirms ‘

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 56.76 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.51 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”